Vaccination for Hepatitis-B & Hepatitis-C

Hepatitis B virus (HBV) is transmitted via blood or sexual contact. People with chronic HBV infection are at increased risk for cirrhosis and liver cancer and require medical care. ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection and vaccination of adults requesting protection from HBV without acknowledgment of a specific risk factor.

 

Recommended doses of currently licensed formulations of hepatitis B vaccine,
by age group and vaccine type
Age Group Single-antigen vaccine Combination vaccine
Recombivax HB Engerix-B Pediarix† Twinrix§
Dose
(μg)¶
Vol(mL) Dose
(μg)¶
Vol(mL) Dose
(μg)¶
Vol (mL) Dose
(μg)¶
Vol (mL)
Infants (<1 yr)
5 0.5 10 0.5 10 0.5 NA** NA
Children (1–10 yrs)
5 0.5 10 0.5 10† 0.5 NA NA
Adolescents
11–15 yrs 10†† 1.0 NA NA NA NA NA NA
11–19 yrs 5 0.5 10 0.5 NA NA NA NA
Adults (≥20 yrs)
10 1.0 20 1.0 NA NA 20§ 1.0
Hemodialysis patients
and other immuno-
compromised persons
<20 yrs§§ 5 0.5 10 0.5 NA NA NA NA
≥20 yrs 40¶¶ 1.0 40*** 2.0 NA NA NA NA

A patient receive the first dose of hepatitis B vaccine from one manufacturer and subsequent doses from another manufacturer. No differences in immune response are observed when vaccines from different manufacturers are used to complete the vaccine series. 

If the vaccine series was interrupted after the first dose, the second dose should be administered as soon as possible. A re-start is not necessary. 

Studies indicate that immunologic memory remains intact for at least 30 years among healthy vaccinated individuals who initiated hepatitis B vaccination >6 months of age. The vaccine confers long-term protection against clinical illness and chronic hepatitis B virus infection. Cellular immunity appears to persist even though antibody levels might become low or decline below detectable levels. Among vaccinated cohorts who initiated hepatitis B vaccination at birth, long-term follow-up studies are ongoing to determine the duration of vaccine-induced immunity.

Hepatitis C is a liver infection caused by the Hepatitis C virus (HCV). Hepatitis C is a blood-borne virus. Today, most people become infected with the Hepatitis C virus by sharing needles or other equipment to inject drugs. For some people, hepatitis C is a short-term illness but for 70%–85% of people who become infected with Hepatitis C, it becomes a long-term, chronic infection. Chronic Hepatitis C is a serious disease than can result in long-term health problems, even death. The majority of infected persons might not be aware of their infection because they are not clinically ill. There is no vaccine for Hepatitis C. The best way to prevent Hepatitis C is by avoiding behaviors that can spread the disease, especially injecting drugs.

 

 

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.